GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Verrica Pharmaceuticals
Shares of Verrica Pharmaceuticals, a dermatology-focused company, reflect the binary risks of biotech. Their price is driven by FDA decisions on a key drug for molluscum contagiosum. The chart is a story of approval and commercial launch hopes, which determine the company's entire value.
Share prices of companies in the market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company developing drugs to treat skin conditions, particularly molluscum contagiosum. We've categorized it under "Pharma: Skin," and the chart below shows how investors value companies addressing unmet needs in dermatology.
Broad Market Index - GURU.Markets
Verrica Pharmaceuticals is a dermatology company developing drugs to treat skin conditions, particularly molluscum contagiosum. As a component of the GURU.Markets index, it addresses unmet needs in dermatology. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
VRCA - Daily change in the company's share price Verrica Pharmaceuticals
For Verrica Pharmaceuticals, a dermatology company, daily volatility reflects sensitivity to FDA decisions and the commercial success of its drugs. This metric is an important element in analyzing the risks and potential of niche pharmaceutical companies.
Daily change in the price of a set of shares in a market segment - Pharma skin
Verrica Pharmaceuticals Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to VRCA, which focuses on dermatology, helps assess how resilient its niche business is to overall industry trends.
Daily change in the price of a broad market stock, index - GURU.Markets
Verrica Pharmaceuticals is a pharmaceutical company focused on dermatology. Its shares are responding to drug commercialization successes and regulatory decisions. The dynamics of this niche healthcare segment are part of a larger and more diverse picture of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Verrica Pharmaceuticals
For Verrica Pharmaceuticals, the year-over-year performance is a story of the commercialization of its first drug. Its market capitalization growth over the past 12 months reflects the successful approval and launch of its treatment for molluscum contagiosum, a fundamental milestone that transformed the company from an R&D company into a commercial enterprise with actual sales.
Annual dynamics of market capitalization of the market segment - Pharma skin
Verrica Pharmaceuticals, Inc. is a commercial-stage dermatology company. Its success hinges on the commercialization of its first approved drug for the treatment of molluscum contagiosum. The chart below illustrates how its focused strategy and the competitive landscape in the dermatology market are impacting its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Verrica is a biopharmaceutical company whose stock performance is driven by the commercialization of its products and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Verrica Pharmaceuticals
Verrica Pharmaceuticals is a dermatology company awaiting approval of its first product. Its monthly performance is entirely dependent on news related to the FDA's decision. Any announcement from the regulator triggers a sharp and strong reaction from investors, shaping its price chart.
Monthly dynamics of market capitalization of the market segment - Pharma skin
Verrica Pharmaceuticals specializes in dermatological treatments. The skin care pharmaceutical sector is growing thanks to innovation and strong demand. The chart below shows how investors assessed the commercial potential of new skin treatments and the overall sentiment in this competitive niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Verrica Pharmaceuticals is a dermatology company with an already approved product. Its stock price now depends less on future discoveries than on the success of commercialization: sales volumes, marketing, and competition. This is the story of how a scientific breakthrough turns into a successful business.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Verrica Pharmaceuticals
Verrica Pharmaceuticals is a dermatology company whose fate is closely tied to regulatory decisions. Its weekly stock price exhibits high volatility ahead of FDA meetings. A positive or negative decision on its key drug is a binary event, causing sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company whose fate is closely tied to regulatory decisions. Its weekly stock price exhibits high volatility ahead of FDA meetings. A positive or negative decision on its key drug is a binary event, causing sharp price fluctuations.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Verrica, a biotech company, lives in a world of its own. Its performance is determined by FDA decisions. A chart comparing it to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
VRCA - Market capitalization of the company Verrica Pharmaceuticals
Verrica Pharmaceuticals' market capitalization chart tells the story of the long and arduous battle to secure FDA approval for the first drug to treat molluscum contagiosum. Its volatile dynamics reflect the rejections and eventual success. It's a visualization of how persistence in biotech can ultimately be rewarded, but the path to that end is extremely risky.
VRCA - Share of the company's market capitalization Verrica Pharmaceuticals within the market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company focused on developing treatments for skin diseases. Its market capitalization reflects its leadership in the treatment of molluscum contagiosum. The chart below shows how its market share is influenced by the commercial success of its first approved drug.
Market capitalization of the market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company that developed the first FDA-approved drug for the treatment of molluscum contagiosum. The chart below shows the overall market capitalization of the skin pharmaceuticals sector. It illustrates how a company can create a new market by offering a solution for a previously untreated, common condition.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows the fight against viral skin diseases. Verrica Pharmaceuticals received approval for the first-ever drug to treat molluscum contagiosum. Its line on the graph tells the story of the long road to commercialization and the attempt to create a new market where no drug existed before.
Book value capitalization of the company, segment and market as a whole
VRCA - Book value capitalization of the company Verrica Pharmaceuticals
Verrica Pharmaceuticals' equity is its financial reserves and the rights to a drug for the treatment of molluscum contagiosum and other skin diseases. Its book value reflects the resources available for commercializing this product. The chart below shows how FDA approval and sales launch impacted this dermatology company's equity base.
VRCA - Share of the company's book capitalization Verrica Pharmaceuticals within the market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company whose first product is designed to treat molluscum contagiosum. Its physical assets are tied to the production and distribution of this drug. The chart shows the company's share of the infrastructure needed to bring its products to market.
Market segment balance sheet capitalization - Pharma skin
Dermatological pharmaceuticals, as the BCap_Seg chart shows, require significant investment in R&D and production. Verrica Pharmaceuticals, when launching its drug, had to invest in creating a reliable manufacturing and commercial infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Verrica Pharmaceuticals' book value represents the capital invested in commercializing its skin treatment. It reflects the financial and material resources (product inventory) that enable the company to bring a real, FDA-approved drug to market.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Verrica Pharmaceuticals
Verrica Pharmaceuticals specializes in dermatology drugs. Its market capitalization is based on the potential of its approved or developing products. The MvsBCap chart will be highly sensitive to sales data and regulatory decisions. For a company with a narrow focus, such news can dramatically change its market valuation.
Market to book capitalization ratio in a market segment - Pharma skin
Verrica Pharmaceuticals is a pharmaceutical company specializing in dermatology. Its value is closely tied to the success of its skin treatments. This metric reflects how investors assess the commercial potential of its products and development pipeline.
Market to book capitalization ratio for the market as a whole
Verrica Pharmaceuticals develops drugs to treat skin diseases. Its market valuation is heavily dependent on the regulatory approval process and subsequent commercial success of its products. This chart shows how investors weigh these regulatory risks against the market potential in dermatology.
Debts of the company, segment and market as a whole
VRCA - Company debts Verrica Pharmaceuticals
Verrica Pharmaceuticals is using capital to commercialize its first FDA-approved drug for dermatological conditions. Bringing a new drug to market requires significant investment in sales, marketing, and manufacturing. This chart shows how the company is funding its transition from R&D to a fully commercialized company.
Market segment debts - Pharma skin
Verrica Pharmaceuticals is a dermatology company focused on commercializing drugs for skin conditions. Transitioning from development to sales requires significant investments in marketing and building a distribution network. This chart shows how Verrica funds this critical stage of its development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Verrica Pharmaceuticals
Verrica Pharmaceuticals, a dermatology company, invests heavily in research and regulatory approvals. This chart shows its debt load. Debt dependence is typical in the pharmaceutical industry, but it could become critical if the company's flagship drug faces delays on its way to market.
Market segment debt to market segment book capitalization - Pharma skin
Verrica Pharmaceuticals is a dermatology company focused on developing treatments for skin conditions. This chart shows the overall debt burden in the specialty pharmaceuticals sector. It helps understand how the company finances its product launches and how its financial structure compares to other players in the niche.
Debt to book value of all companies in the market
Verrica Pharmaceuticals is a dermatology company focused on developing treatments for skin diseases. The overall debt burden shown in the graph impacts the entire healthcare system. It affects both patients' purchasing power and clinic budgets, which ultimately determines the market potential of new drugs.
P/E of the company, segment and market as a whole
P/E - Verrica Pharmaceuticals
The chart for Verrica Pharmaceuticals, focused on dermatology, shows how investors value its key drugs. The dynamics of this indicator reflect the market's confidence in the commercial success of its skin treatment products and the company's ability to secure regulatory approval and earn the trust of doctors and patients.
P/E of the market segment - Pharma skin
This chart shows the average P/E for the pharmaceutical industry, where Verrica occupies its niche. Comparing the company's P/E to this general metric helps understand how the market views the commercial potential of its dermatology products compared to other, more diversified pharmaceutical companies.
P/E of the market as a whole
Verrica Pharmaceuticals is a dermatology company developing medications for skin diseases. Its lead product is designed to treat molluscum contagiosum, a common condition in children. This chart shows sentiment in the pharmaceutical sector. It helps understand how the market views the commercial potential of Verrica's products and how regulatory decisions impact its valuation relative to other companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Verrica Pharmaceuticals
Verrica Pharmaceuticals specializes in the development and commercialization of drugs for the treatment of skin diseases. Its success depends on the approval and sales of its lead product, a treatment for molluscum contagiosum. This chart shows analysts' sales forecasts for this drug, which is the company's primary driver.
%20P%2FE%20Verrica%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Verrica-Pharmaceuticals&v=1772650395472 "Chart of the company's future (projected) P/E Verrica Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company developing drugs for the treatment of skin diseases. Its flagship product is designed to treat molluscum contagiosum. This chart shows how its future revenue expectations compare to the industry average, reflecting the market potential of its niche products.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-skin&v=1772650395500 "Future (projected) P/E graph of the market segment - Pharma skin")
Future (projected) P/E of the market as a whole
Verrica Pharmaceuticals is a dermatology company developing drugs for the treatment of skin diseases. Its success depends on regulatory approval and product commercialization. This chart, showing the market's risk appetite, influences the valuation of biotech companies. Investor optimism facilitates raising capital for marketing and launching new drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772650395520 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Verrica Pharmaceuticals
Verrica Pharmaceuticals is focused on developing drugs to treat skin diseases. Its profitability depends on the commercial success of its first approved product for molluscum contagiosum. This chart illustrates the transition from the loss-making R&D stage to revenue generation and the importance of successfully bringing even a single drug to market.
Profit of companies in the market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company whose first drug, YCANTH™, was approved for the treatment of molluscum contagiosum. It is an example of a company that successfully navigated the path from development to commercialization. This graph of overall pharmaceutical profitability demonstrates how the approval of even one niche drug can dramatically change the financial position of a biotech company.
Overall market profit
Verrica Pharmaceuticals specializes in skin treatments. Demand for its products is determined by both medical indications and patient preferences. This graph, reflecting the overall economic situation, influences household incomes and their willingness to spend on treatments for non-life-threatening conditions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Verrica Pharmaceuticals
Verrica Pharmaceuticals is a dermatology company focused on developing treatments for skin diseases. Its flagship product is designed to treat molluscum contagiosum. This chart shows how analysts assess the commercial potential of its approved and developmental drugs and future profitability.
%20profit%20of%20the%20company%20Verrica%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Verrica-Pharmaceuticals&v=1772650395590 "Graph of future (projected) profit of the company Verrica Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company whose flagship product is designed to treat molluscum contagiosum, a common viral skin disease in children. The company is bringing to market the first FDA-approved treatment for this condition. This chart shows profitability projections for the pharmaceutical sector, providing context for assessing the commercial potential of such niche drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-skin&v=1772650395647 "Graph of future (predicted) profits of companies in a market segment - Pharma skin")
Future (predicted) profit of the market as a whole
Verrica Pharmaceuticals specializes in dermatology, developing medications for the treatment of skin diseases. Demand for its products depends on both the healthcare system and patients' willingness to pay for treatment. This chart, showing overall profit expectations, provides insight into the economic climate affecting the budgets of both consumers and clinics.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772650395750 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Verrica Pharmaceuticals
Verrica Pharmaceuticals specializes in dermatology drugs. This chart shows how investors assess the commercial potential of its products. The market capitalization-to-sales ratio is a key indicator after drug approval, reflecting market share expectations.
P/S market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company developing drugs to treat skin conditions. This chart shows the average revenue estimate for the pharmaceutical sector. It helps assess how the market perceives the potential revenue from Verrica's drugs, which address unmet needs in the treatment of common skin conditions.
P/S of the market as a whole
Verrica Pharmaceuticals specializes in developing drugs for the treatment of dermatological diseases. Their lead candidate is designed for the treatment of molluscum contagiosum, a common condition in children. This chart, showing company valuations based on actual revenue, helps understand investors' expectations for the future commercial success of VRCA's niche dermatological drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Verrica Pharmaceuticals
Verrica Pharmaceuticals specializes in developing drugs for the treatment of skin diseases. This chart shows how the market estimates future revenue from its first approved product for the treatment of molluscum contagiosum. This estimate depends on the success of the commercial launch and the potential of its other dermatological drug candidates.
%20P%2FS%20Verrica%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Verrica-Pharmaceuticals&v=1772650395922 "The graph of the company's future (projected) P/S Verrica Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company developing medications for the treatment of skin diseases. Its lead product targets molluscum contagiosum, a common childhood condition. This chart shows how the market assesses the commercial potential of its specialized medications compared to the pharmaceutical industry.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20skin&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-skin&v=1772650395928 "Future (projected) P/S market segment graph - Pharma skin")
Future (projected) P/S of the market as a whole
Verrica Pharmaceuticals is a dermatology company whose first drug is designed to treat molluscum contagiosum. This graph, reflecting overall healthcare spending expectations, is important for Verrica's commercial success. Economic confidence influences the willingness of patients and insurers to pay for new, more effective treatments for skin conditions.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772650395953 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Verrica Pharmaceuticals
Verrica Pharmaceuticals is a dermatology company focused on developing treatments for skin diseases. This chart shows sales revenue from its first FDA-approved product for the treatment of molluscum contagiosum. The growth here reflects the successful commercial launch and acceptance of the new drug by doctors and patients.
Sales of companies in the market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company focused on the development and commercialization of drugs for the treatment of skin diseases. Its business is segmented by product, the flagship of which is a treatment for molluscum contagiosum. This chart shows the revenue from one of its key drugs, reflecting its commercial launch and market acceptance.
Overall market sales
Verrica Pharmaceuticals is a dermatology company developing drugs to treat skin conditions. Its first product targets molluscum contagiosum, a common childhood condition. The company's success depends on regulatory approval and commercialization of its products, an example of creating value by addressing an unmet medical need.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Verrica Pharmaceuticals
Verrica Pharmaceuticals is a dermatology company focused on developing treatments for skin diseases. Its sales forecast is based on the commercial success of its first approved drug for molluscum contagiosum. It reflects expectations for its acceptance by physicians and patients.
%20sales%20of%20the%20company%20Verrica%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Verrica-Pharmaceuticals&v=1772650396004 "Schedule of future (projected) sales of the company Verrica Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma skin
Verrica Pharmaceuticals is focused on developing and commercializing drugs for the treatment of dermatological diseases. This chart shows expectations for the entire skin pharmaceutical sector. It allows analysts to assess the demand for new treatments for skin conditions, such as molluscum contagiosum, predicted for the entire industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-skin&v=1772650396035 "Schedule of future (projected) sales of companies in the market segment - Pharma skin")
Future (projected) sales of the market as a whole
Verrica Pharmaceuticals specializes in dermatological medications. Demand for its products depends on the number of visits to dermatologists and patients' willingness to pay for treatment. This graph of overall sales forecasts reflects the overall economic health, which influences people's spending on specialized medical care.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772650396050 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Verrica Pharmaceuticals
Verrica Pharmaceuticals is a dermatology company focused on developing drugs for the treatment of skin diseases. This chart shows its financial trajectory, where revenues from its first approved products begin to offset the high costs of research, development, and commercial launch, paving the way to sustainable profitability in the pharmaceutical industry.
Market segment marginality - Pharma skin
Verrica Pharmaceuticals is a dermatology company developing drugs for the treatment of skin conditions. Their profitability depends on the successful commercialization of already approved products and the effectiveness of R&D on new candidates. The chart shows how their focused business model competes in the pharmaceutical market.
Market marginality as a whole
Verrica Pharmaceuticals is a dermatology company developing drugs for the treatment of skin diseases. Its lead candidate is designed to treat molluscum contagiosum. This graph shows average profitability, but for VRCA, success depends on regulatory approval and the commercial launch of a first-of-its-kind drug that addresses an unmet medical need.
Employees in the company, segment and market as a whole
Number of employees in the company Verrica Pharmaceuticals
Verrica Pharmaceuticals is a dermatology company that has launched its first drug. This timeline reflects the company's transformation: from a small R&D team to a larger organization with a fully-fledged sales and marketing department necessary for commercializing an approved product.
Share of the company's employees Verrica Pharmaceuticals within the market segment - Pharma skin
Verrica Pharmaceuticals specializes in developing drugs for the treatment of skin diseases. Its focus on dermatology requires a team with deep expertise in this field. This metric reflects its scale and concentration of talent needed to bring new treatments to market.
Number of employees in the market segment - Pharma skin
Verrica Pharmaceuticals specializes in developing dermatological drugs. This chart shows employment in the skin pharmaceuticals sector. The growing number of specialists in this field indicates high demand for new treatments for skin conditions, from acne to viral infections, creating a market for Verrica's approved drugs.
Number of employees in the market as a whole
Verrica Pharmaceuticals specializes in dermatology medications. Demand in this area depends on patient volume and insurance coverage. The increase in overall employment, visible in this graph, may correlate with an increase in the number of people with health insurance, which increases access to treatment and demand for Verrica's products.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Verrica Pharmaceuticals (VRCA)
Verrica Pharmaceuticals Inc. is a dermatology company developing drugs for the treatment of skin diseases. A moderate value on this chart may indicate that the company is in the commercialization stage. Value here is a balance between patents and the need to maintain a marketing and sales staff.
%20of%20the%20company%20Verrica%20Pharmaceuticals%20(VRCA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Verrica-Pharmaceuticals-VRCA&v=1772650396129 "Chart of market capitalization per employee (in thousands of dollars) of the company Verrica Pharmaceuticals (VRCA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company developing drugs for the treatment of skin diseases. In the pharmaceutical industry, cost per employee reflects the market valuation of its product portfolio and clinical development. This chart allows us to assess how much investors believe in the commercial potential of its drugs compared to other players in the sector.
%20by%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-skin&v=1772650396150 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma skin")
Market capitalization per employee (in thousands of dollars) for the overall market
Verrica Pharmaceuticals is a dermatology company whose primary product is designed to treat molluscum contagiosum, a common skin condition. The chart shows how the market values a company focused on solving a specific medical problem with a small but dedicated team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772650396165 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Verrica Pharmaceuticals (VRCA)
Verrica Pharmaceuticals is a dermatology company whose first drug, Ycanth™, was approved for the treatment of molluscum contagiosum. This chart shows how successfully the company is transitioning from R&D to commercialization. It measures how effectively their sales team can promote this niche drug to doctors and patients, generating profit per employee after years of investment in development.
%20Chart%20Verrica%20Pharmaceuticals%20(VRCA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Verrica-Pharmaceuticals-VRCA&v=1772650396182 "Company Profit Per Employee (in thousands of dollars) Chart Verrica Pharmaceuticals (VRCA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company developing drugs for the treatment of skin diseases. Their business model is focused on bringing FDA-approved products to market. This chart shows how effectively their team commercializes their developments and compares their operating profit per employee with their competitors.
%20in%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-skin&v=1772650396206 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma skin")
Profit per employee (in thousands of dollars) for the market as a whole
Verrica Pharmaceuticals is a dermatology company whose first product, YCANTH, was approved by the FDA. This metric reflects the transition from R&D to commercialization. It shows how successfully their sales team is promoting the new drug to physicians, and whether revenue from the product is beginning to cover all operating and research expenses.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772650396217 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Verrica Pharmaceuticals (VRCA)
Verrica Pharmaceuticals is a dermatology company commercializing its first drug. This chart shows the transition from R&D to sales. The increase in revenue per employee reflects the successful product launch, its acceptance by physicians and patients, and the effectiveness of a small commercial team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Verrica-Pharmaceuticals-VRCA&v=1772650396263 "Sales chart per company employee Verrica Pharmaceuticals (VRCA)")
Sales per employee in the market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company whose first drug, Ycanth, is designed to treat molluscum contagiosum. It's a niche market. This chart compares Verrica's revenue per employee to the industry average. It demonstrates how effective their sales team is in promoting and selling this highly specialized drug.
Sales per employee for the market as a whole
Verrica Pharmaceuticals is a dermatology company. Their key product (Ycanth) is the first FDA-approved treatment for molluscum contagiosum. They are now commercially active. This chart shows how effectively their sales team promotes this unique drug to doctors, and how much revenue each employee generates.
Short shares by company, segment and market as a whole
Shares shorted by company Verrica Pharmaceuticals (VRCA)
Verrica Pharmaceuticals (VRCA) is a dermatology company whose key drug for the treatment of molluscum contagiosum has been struggling to gain FDA approval. Regulatory delays are burning cash and eroding confidence. This chart shows the number of investors who doubt the drug's commercial success, even if it reaches market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Verrica-Pharmaceuticals-VRCA&v=1772650396489 "Short Shares Chart for the Company Verrica Pharmaceuticals (VRCA)")
Shares shorted by market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company whose first drug (Ycanth) was approved for the treatment of molluscum contagiosum, a niche skin condition. This chart shows the odds against the niche biotech sector. It reflects investor concerns about the market size for this drug and the commercial success of its launch.
Shares shorted by the overall market
Verrica (VRCA) is a biotech company working on skin diseases. It's a speculative R&D play. When this market fear indicator rises, investors' risk appetite plummets. They sell off unprofitable stocks like VRCA, whose fate depends on R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Verrica Pharmaceuticals (VRCA)
Verrica Pharmaceuticals is a dermatology company whose lead drug (Ycanth) for molluscum contagiosum received FDA approval. This chart shows how the market reacted to this binary risk: "oversold" (below 30) on news of the FDA rejection and "overbought" (above 70) at the time of the long-awaited approval.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Verrica-Pharmaceuticals-VRCA&v=1772650396582 "RSI 14 indicator chart for the company's stock Verrica Pharmaceuticals (VRCA)")
RSI 14 Market Segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company developing drugs for the treatment of skin diseases. Their lead candidate (VP-102) is designed to treat molluscum contagiosum. This chart measures the collective excitement in the dermatology biotech sector. It helps separate VRCA volatility from the overall industry trend.
RSI 14 for the overall market
For Verrica Pharmaceuticals, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VRCA (Verrica Pharmaceuticals)
Verrica Pharmaceuticals is a dermatology company whose flagship drug (Ycanth) was the first FDA-approved treatment for molluscum contagiosum. This chart shows the average analyst forecast. Their targets are based on the pace of Ycanth's commercial launch and its potential for treating other skin conditions.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VRCA-Verrica-Pharmaceuticals&v=1772650396662 "A chart showing analyst consensus forecasts for the expected stock price. VRCA (Verrica Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price VRCA (Verrica Pharmaceuticals)
Verrica Pharmaceuticals is a dermatology company whose flagship drug, Ycanth, became the first FDA-approved treatment for molluscum contagiosum. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their expectations for the commercial success of this launch and market penetration.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VRCA-Verrica-Pharmaceuticals&v=1772650396690 "A chart showing the difference between the consensus forecast and the actual stock price. VRCA (Verrica Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma skin
Verrica Pharmaceuticals is a dermatology company whose flagship drug, Ycanth, is designed to treat molluscum contagiosum (a skin condition in children). This chart shows analysts' overall expectations for the skin pharmaceutical sector. It reflects whether experts believe this niche drug will be commercially successful.
Analysts' consensus forecast for the overall market share price
Verrica Pharmaceuticals is a dermatology company whose key product (Ycanth) is approved for the treatment of molluscum contagiosum, a common skin condition in children. This chart shows overall market sentiment. For Verrica, as a company in the commercialization stage, overall optimism is important for funding, but their growth is more dependent on physician and insurer acceptance of their new drug.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Verrica Pharmaceuticals
Verrica is a dermatology company whose flagship (and first approved) product (Ycanth) is an over-the-counter treatment for molluscum contagiosum, a viral skin disease in children. This chart is a summary of their commercial launch. It reflects their (slow) pace of adoption, their ability to secure reimbursement from insurers, and their struggle to capture new markets.
AKIMA Market Segment Index - Pharma skin
Verrica Pharmaceuticals (VRCA) is a dermatology company focused on treating skin conditions. Their flagship product, YCANTH, is the first FDA-approved treatment for molluscum contagiosum. This chart shows the segment average. It helps investors assess how the commercialization of this unique product compares to the average in the skin pharmaceutical sector.
The AKIM Index for the overall market
Verrica Pharmaceuticals is a dermatology company that developed YCANTH, the first FDA-approved treatment for molluscum contagiosum. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this unique product's commercialization story compares to overall economic trends in healthcare.
